At her first prenatal appointment for her first pregnancy, Shana Westlake of Beacon, New York, remembers entering her OB-GYN's office full of anxiety. "They took my blood pressure, and it was ...
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...
Hidden Guests” explores how the emerging field of microchimerism is upending medicine, genetics, and our sense of self.
This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...
CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS ...
12d
South Carolina needs large-animal veterinarians. Will a (pricey) new Clemson program fill the void?
Erika Berr is part of a tiny army of vets caring for SC’s farm animals, supporting reproductive health and farmer profits. Clemson intends to train more.
Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in ...
Opinion
4dOpinion
Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
There may be good reasons to object to using animals as living organ factories, including welfare concerns. But the rationale behind the NIH ban that human cells could make pigs too human rests on a ...
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...
About KOMZIFTI™ KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation ...
Robust and clinically meaningful benefits across all three key markers of disease - 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent ...
The following highlights showcase key research presented at the European Society for Medical Oncology (ESMO) 2025 Congress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback